



## Pneumococcal diagnosis and serotypes in childhood community-acquired pneumonia ☆☆☆

Mohamed A. Elemraid <sup>a,b,\*</sup>, Andrew D. Sails <sup>c</sup>, Matthew F. Thomas <sup>d,e</sup>, Stephen P. Rushton <sup>e</sup>, John D. Perry <sup>f</sup>, Gary J.A. Eltringham <sup>c</sup>, David A. Spencer <sup>d</sup>, Katherine M. Eastham <sup>g</sup>, Fiona Hampton <sup>h</sup>, Andrew R. Gennery <sup>a,b</sup>, Julia E. Clark <sup>a,b</sup>  
and On behalf of the North East of England Paediatric Respiratory Infection Study Group

<sup>a</sup> Department of Paediatric Infectious Disease and Immunology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK

<sup>b</sup> Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE1 7RU, UK

<sup>c</sup> Health Protection Agency Public Health Laboratory Newcastle, Royal Victoria Infirmary, Newcastle upon Tyne N1 4LP, UK

<sup>d</sup> Department of Respiratory Paediatrics, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK

<sup>e</sup> School of Biology, Newcastle University, Newcastle upon Tyne NE1 7RU, UK

<sup>f</sup> Department of Microbiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK

<sup>g</sup> Department of Paediatrics, Sunderland Royal Hospital, Sunderland SR4 7TP, UK

<sup>h</sup> Department of Paediatrics, James Cook University Hospital, Middlesbrough TS4 3BW, UK

### ARTICLE INFO

#### Article history:

Received 29 October 2012

Received in revised form 12 February 2013

Accepted 19 February 2013

Available online 26 March 2013

#### Keywords:

Diagnosis

Paediatrics

Pneumococcal conjugate vaccine

Pneumonia

Serotype

*Streptococcus pneumoniae*

Urinary pneumococcal antigen

### ABSTRACT

The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced routinely in the UK from September 2006 and replaced by PCV13 in 2010. In a prospective study from 2009 to 2011 of 160 children aged  $\leq 16$  years with radiologically confirmed pneumonia, likely pneumococcal infections were identified in 26%. Detection of pneumococci was improved with polymerase chain reaction compared to culture (21.6% versus 6% of children tested,  $P = 0.0004$ ). Where serotyping was possible, all ( $n = 23$ ) were non-PCV7 but PCV13 serotypes; 1 (43.5%), 3 (21.7%), 7A/F, and 19A (17.4% each).

© 2013 Elsevier Inc. All rights reserved.

### 1. Introduction

*Streptococcus pneumoniae* is the leading bacterial cause of paediatric community-acquired pneumonia (PCAP) (Rudan et al., 2008). The 7-valent pneumococcal conjugate vaccine (PCV7) (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) was added into the UK immunisation schedule from September 2006; subsequently replaced by PCV13 from April 2010 (additional serotypes 1, 3, 5, 6A, 7F, and

19A). Three vaccine doses are administered at the age of 2, 4, and 13 months. When the vaccine was introduced, a catch up programme was offered to all children born between September 2004 and September 2006. This vaccination programme would thus be expected to impact upon the pneumococcal serotypes implicated in PCAP.

Pathogens are difficult to identify in children with pneumonia, with blood culture and serological testing often negative due to minimal presence of bacteremia (Brent et al., 2006; Korppi et al., 2008). This paucity of *S. pneumoniae* isolation makes examining pneumococcal serotype distribution in PCAP difficult, with no UK, and little worldwide, data. Using non-culture techniques including pneumococcal detection by polymerase chain reaction (PCR) in blood (Resti et al., 2010) and pleural fluid (Strachan et al., 2012), pneumococcal antigen detection in urine (Charkaluk et al., 2006), and pneumococcal serotype detection by PCR (Esposito et al., 2012; Resti et al., 2010), we sought to determine the contribution of *S. pneumoniae* and specific serotypes to the aetiology of PCAP.

☆ Conflicts of interest and source of funding: This study was supported by a grant from Pfizer Vaccines UK (No. 0887X1-4479). JEC and DAS received unconditional research support from Pfizer. The sponsor had no role in the study design, data collection, analysis or interpretation, and writing of the manuscript.

☆☆ Contributors: JEC, ADS and DAS developed the original study concept. MAE collected and managed the data. ADS, JDP, GJAE and MAE performed the laboratory analyses. All authors were involved in the interpretation of the results and writing of this article.

\* Corresponding author. Tel.: +44-0-191-282-1343; fax: +44-0-191-282-4724.

E-mail address: [mohamed.elemraid@ncl.ac.uk](mailto:mohamed.elemraid@ncl.ac.uk) (M.A. Elemraid).

We included urinary pneumococcal antigen detection by Binax Now as being indicative of invasive pneumococcal infection for several reasons. It has good sensitivity (100%) and specificity (56%) in children with suspected pneumococcal disease (Charkaluk et al., 2006), but is confounded as a diagnostic test by nasopharyngeal carriage where up to 21% may be positive (Hamer et al., 2002). Urinary pneumococcal antigen may also be positive in 4% healthy nasopharyngeal culture-negative children (Hamer et al., 2002), although given the increased sensitivity of PCR compared to culture, it is likely that nasopharyngeal culture-negative children would have pneumococcal carriage if tested by PCR (Turner et al., 2011). Thus, a positive urinary antigen in a child with pneumonia and no pneumococcal nasopharyngeal carriage by PCR is likely to reflect invasive pneumococcal disease.

## 2. Materials and methods

### 2.1. Study population

From October 2009 to March 2011 children aged  $\leq 16$  years old with clinical and radiological features suggestive of pneumonia admitted to any of three hospitals in North East England were prospectively enrolled. Informed consent was obtained from parents and assent from older children. Ethical and Caldicott approvals were granted (Newcastle and North Tyneside Research Ethics Committee (No: 08/H0906/105), and Research Approval Board at South Tees Hospitals NHS Trust (No: 2008075)).

Pneumonia was defined by signs and symptoms suggestive of lower respiratory tract infection and chest radiographic findings consistent with pneumonia as determined initially by the local paediatrician. Exclusions included being resident outside North East England, clinical bronchiolitis, hospitalisation in the preceding three weeks, or normal chest radiograph after review by a radiologist. Chest radiographs were first reported by local radiologists then reviewed by a second consultant cardiothoracic radiologist at the regional centre. Radiographic findings were categorised into lobar, patchy, or perihilar according to World Health Organization criteria (Cherian et al., 2005). Conjugate pneumococcal vaccination history was ascertained.

### 2.2. Laboratory procedures

Blood samples were collected for serum, blood culture (BacT/ALERT®, bioMérieux) and pneumococcal PCR testing. Nasopharyngeal aspirates (NPA) were obtained from infants, and placed in 0.9% sodium chloride transport solution. For older children, bacterial nasopharyngeal swab (NPS) was collected. Expectored sputum and tracheobronchial secretions (TBS) (sampled via endotracheal tube or bronchoalveolar lavage) and pleural fluids were tested when collected. Secretions were inoculated into plates of Columbia agar (Oxoid) supplemented with 5% horse blood (CBA) and Oxoid brain-heart infusion broth with 10% serum (Oxoid). Broths were incubated

overnight at 37 °C and sub-cultured (10  $\mu$ L) into CBA plates for incubation at 37°C in 5% carbon dioxide for 48 hours. Pneumococcal isolates were identified by standard methods including latex agglutination and API 32 STREP (bioMérieux). Urine samples were tested for pneumococcal antigen using Binax NOW (Inverness Medical Innovations Ltd, Ireland). Not every child had all tests performed.

Total nucleic acid was extracted from blood, respiratory secretions, culture-negative pleural fluid, and pneumococcal antigen positive urine samples for PCR using an EasyMag automated nucleic acid extraction instrument (bioMérieux) and the resulting nucleic acid used as template in a *S. pneumoniae* specific PCR targeting the pneumolysin gene (and autolysin gene for pleural fluids) (Corless et al., 2001). Any recovered *S. pneumoniae* was serotyped using a multiplexed xMAP immunoassay for detection of serotype-specific *S. pneumoniae* antigens (Sheppard et al., 2011). This assay identifies PCV13-serotypes plus serotype 8.

### 2.3. Diagnostic criteria for pneumococcal infection and statistical analysis

*S. pneumoniae* was considered a definite or probable pathogen when detected from a sterile site, TBS or urine samples. Pneumococcal detection in NPA/NPS or sputum was considered a possible pathogen and likely to represent nasopharyngeal carriage in children (Table 1). Detection rates of pathogens are expressed as proportions of those tested. Fisher's exact test was used to compare different detection methods and odds ratios and 95% confidence intervals were calculated. Data were analysed using Epi Info™ 7.

## 3. Results

Of 160 children, 56% were male and 69% aged  $< 5$  years, median age 2.6 years. All received antibiotics, none died. Radiographs showed 61% lobar consolidation, and 42.5% pleural effusion. Forty (25%) children had empyema. Based on age, pneumococcal vaccination uptake among 119 eligible children was 94% (89 had PCV7, 10 PCV13, and 13 received combinations of each) (online supplement). Pneumococci were detected from any site in 64% of children (103/160). *S. pneumoniae* was identified from nasopharyngeal secretions by culture in 7% (10/141) and by PCR in 63% (76/121); and from sterile sites in 17.4% (24/138); by culture in 6% (8/132); compared with PCR in 21.6% (21/97),  $P = 0.0004$ .

*S. pneumoniae* was the likely (definite/probable) pathogen in 26% (39/149); 20.8% (21/101) and 37.5% (18/48) tested among those aged  $< 5$  and  $\geq 5$  years respectively. Of the 39 pneumococcal infections, 21 children had empyema. Pneumococcal infections among those who received PCV7 was 26.5% (22/83), compared to 10.5% (2/19) for those who either had PCV13 alone or doses of both ( $P = 0.182$ ). A serotype was identified in 82% tested (23/28); serotypes 1 ( $n = 10$ ), 3 ( $n = 5$ ), 7A/F and 19A ( $n = 4$  each) (Table 2). Apart from two children who

**Table 1**  
Laboratory investigations and diagnostic criteria of pneumococcal infection.

Sample	Pathogen/antigen	Tests <sup>a</sup>	Diagnosis of causative pathogens	
			Definite/probable	Possible
Blood	<i>S. pneumoniae</i>	Culture/real-time PCR	Growth/positive	–
Nasopharyngeal secretions, sputum	<i>S. pneumoniae</i>	Culture/real-time PCR	–	Growth/positive
Tracheobronchial secretions (endotracheal/bronchoalveolar lavage)	<i>S. pneumoniae</i>	Culture/real-time PCR	Growth/positive	–
Pleural fluid	<i>S. pneumoniae</i>	Culture/real-time PCR	Growth/positive	–
	Pneumococcal antigen	ELISA	Positive	–
Urine	Pneumococcal antigen	Binax NOW	Positive	–

<sup>a</sup> ELISA, enzyme-linked immunosorbent assay.

Download English Version:

<https://daneshyari.com/en/article/6116121>

Download Persian Version:

<https://daneshyari.com/article/6116121>

[Daneshyari.com](https://daneshyari.com)